DE69723024D1 - Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung zur oralen Verabreichung enthaltend Nifedipin als Wirkstoff - Google Patents

Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung zur oralen Verabreichung enthaltend Nifedipin als Wirkstoff

Info

Publication number
DE69723024D1
DE69723024D1 DE69723024T DE69723024T DE69723024D1 DE 69723024 D1 DE69723024 D1 DE 69723024D1 DE 69723024 T DE69723024 T DE 69723024T DE 69723024 T DE69723024 T DE 69723024T DE 69723024 D1 DE69723024 D1 DE 69723024D1
Authority
DE
Germany
Prior art keywords
oral administration
pharmaceutical compositions
controlled
release pharmaceutical
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69723024T
Other languages
English (en)
Other versions
DE69723024T2 (de
Inventor
Roberto Valducci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valpharma SpA
Original Assignee
Valpharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma SpA filed Critical Valpharma SpA
Publication of DE69723024D1 publication Critical patent/DE69723024D1/de
Application granted granted Critical
Publication of DE69723024T2 publication Critical patent/DE69723024T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
DE69723024T 1996-09-27 1997-09-17 Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung zur oralen Verabreichung enthaltend Nifedipin als Wirkstoff Expired - Fee Related DE69723024T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI961983 1996-09-27
IT96MI001983A IT1284604B1 (it) 1996-09-27 1996-09-27 Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva

Publications (2)

Publication Number Publication Date
DE69723024D1 true DE69723024D1 (de) 2003-07-31
DE69723024T2 DE69723024T2 (de) 2004-04-29

Family

ID=11374935

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69723024T Expired - Fee Related DE69723024T2 (de) 1996-09-27 1997-09-17 Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung zur oralen Verabreichung enthaltend Nifedipin als Wirkstoff

Country Status (13)

Country Link
US (1) US5871775A (de)
EP (1) EP0838218B1 (de)
JP (1) JPH10152440A (de)
CN (1) CN1110304C (de)
AT (1) ATE243499T1 (de)
AU (1) AU719075B2 (de)
BR (1) BR9706214A (de)
CA (1) CA2216277C (de)
DE (1) DE69723024T2 (de)
ES (1) ES2202528T3 (de)
IT (1) IT1284604B1 (de)
NZ (1) NZ328783A (de)
ZA (1) ZA978099B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20040219210A1 (en) * 2003-05-01 2004-11-04 Jian-Hwa Guo Controlled release solid dosage nifedipine formulations
EP1830822A1 (de) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stabile pharmazeutische zusammensetzung mit einer wirksubstanz in form einer festen lösung
CN101272848B (zh) * 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (de) * 2007-01-26 2009-12-02 Isp Investments Inc. Verfahren zur herstellung einer formulierung für sprühgetrocknete produkte
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
DE102007048705A1 (de) 2007-10-11 2009-04-16 Bayer Healthcare Ag Amorphe Formulierung
WO2014016842A1 (en) * 2012-07-23 2014-01-30 Symed Labs Limited Amorphous coprecipitates of rivaroxaban
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
CN109730967B (zh) * 2019-02-19 2021-08-03 广东工业大学 一种硝苯地平固体分散体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
ATE33348T1 (de) * 1983-11-30 1988-04-15 Siegfried Ag Coronartherapeutikum in form von weichgelatinekapseln.
JPS6136213A (ja) * 1984-07-27 1986-02-20 Rooto Seiyaku Kk 口腔用組成物
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
CN1120435A (zh) * 1994-01-04 1996-04-17 贵州泰康中医保健技术有限公司 硝苯吡啶缓释胶囊
CN1129103A (zh) * 1995-02-14 1996-08-21 永信药品工业股份有限公司 硝苯吡啶剂型的开发
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo

Also Published As

Publication number Publication date
AU719075B2 (en) 2000-05-04
JPH10152440A (ja) 1998-06-09
ITMI961983A1 (it) 1998-03-27
ZA978099B (en) 1998-03-27
CN1183960A (zh) 1998-06-10
NZ328783A (en) 1998-02-26
EP0838218B1 (de) 2003-06-25
US5871775A (en) 1999-02-16
CN1110304C (zh) 2003-06-04
CA2216277C (en) 2003-06-10
BR9706214A (pt) 1999-05-04
IT1284604B1 (it) 1998-05-21
CA2216277A1 (en) 1998-03-27
DE69723024T2 (de) 2004-04-29
EP0838218A1 (de) 1998-04-29
AU3756797A (en) 1998-04-02
ES2202528T3 (es) 2004-04-01
ATE243499T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
DE69723024D1 (de) Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung zur oralen Verabreichung enthaltend Nifedipin als Wirkstoff
DK0723435T3 (da) Oral doseringsform af metoprolol til administration én gang dagligt
EP1468679A3 (de) Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe
NO975872D0 (no) Formuleringer for kontrollert frigjöring av lite opplöselige medikamenter
DE69206345D1 (de) Arzneimittel zur intranasalen Verabreichung, die Ketorolac R enthalten.
FI94094B (fi) Kantajakoostumus kestovaikutteiselle lääkeainevalmisteelle
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
DK0510404T3 (da) Gastroresistente farmaceutiske formuleringer til oral administration indeholdende galdesyresalte
DE60001835T2 (de) Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DE60042168D1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
DE69301742T2 (de) Darreichungsformen mit verlaengerter Wirkstoffreigabe
IL122719A0 (en) Controlled release pharmaceutical compositions for oral administration containing nifedipine as active substance

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee